Versatility of 7-substituted coumarin molecules as antimycobacterial agents, neuronal enzyme inhibitors and neuroprotective agents

Molecules

Volumn 22, Issue 10, 2017, Pages

  Kapp, Erika ^a   Visser, Hanri ^b   Sampson, Samantha L ^b   Malan, Sarel F ^a   Streicher, Elizabeth M ^b   Foka, Germaine B ^a   Warner, Digby F ^c   Omoruyi, Sylvester I ^a   Enogieru, Adaze B ^a   Ekpo, Okobi E ^a   Zindo, Frank T ^a   Joubert, Jacques ^a  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Albumin binding; Cholinesterase inhibitor; Coumarin; Monoamine oxidase B inhibitor; Mycobacterium tuberculosis; Neuroprotection; Structure activity relationship

Indexed keywords

ANTIINFECTIVE AGENT; CHOLINESTERASE INHIBITOR; COUMARIN DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; NEUROPROTECTIVE AGENT; PROTEIN BINDING;

ANIMAL; ANTIBIOTIC RESISTANCE; BINDING SITE; CELL LINE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CRICETULUS; DRUG EFFECT; HUMAN; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BINDING SITES; CELL LINE; CELL SURVIVAL; CHOLINESTERASE INHIBITORS; COUMARINS; CRICETULUS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MONOAMINE OXIDASE INHIBITORS; MYCOBACTERIUM TUBERCULOSIS; NEUROPROTECTIVE AGENTS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85030765376     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules22101644     Document Type: Article

References (59)

1. Brown, D.G.; Lister, T.; May-Dracka, T.L. New natural products as new leads for antibacterial drug discovery. Bioorg. Med. Chem. Lett. 2014, 24, 413–418. [CrossRef] [PubMed]
2. Hu, Y.Q.; Xu, Z.; Zhang, S.; Wu, X.; Ding, J.W.; Lv, Z.S.; Feng, L.S. Recent developments of coumarin-containing derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 2017, 136, 122–130. [CrossRef] [PubMed]
3. Keri, R.S.; Sasidhar, B.S.; Nagaraja, B.M.; Santos, M.A. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents. Eur. J. Med. Chem. 2015, 100, 257–269. [CrossRef] [PubMed]
4. Stanley, S.A.; Kawate, T.; Iwase, N.; Shimizu, M.; Clatworthy, A.E.; Kazyanskaya, E.; Sacchettini, J.C.; Ioerger, T.R.; Siddiqi, N.A.; Minami, S.; et al. Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. Proc. Natl. Acad. Sci. USA 2013, 110, 11565–11570. [CrossRef] [PubMed]
5. Heide, L. New aminocoumarin antibiotics as gyrase inhibitors. Int. J. Med. Microbiol. 2014, 304, 31–36. [CrossRef] [PubMed]
6. Schroder, W.; Goerke, C.; Wolz, C. Opposing effects of aminocoumarins and fluoroquinolones on the SOS response and adaptability in Staphylococcus aureus. J. Antimicrob. Chemother. 2013, 68, 529–538. [CrossRef] [PubMed]
7. Collin, F.; Karkare, S.; Maxwell, A. Exploiting bacterial DNA gyrase as a drug target: Current state and perspectives. Appl. Microbiol. Biotechnol. 2011, 92, 479–497. [CrossRef] [PubMed]
8. Flatman, R.H.; Howells, A.J.; Heide, L.; Fiedler, H.; Maxwell, A. Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action. Antimicrob. Agents Chemother. 2005, 49, 1093–1100. [CrossRef] [PubMed]
9. Edwards, M.J.; Williams, M.A.; Maxwell, A.; McKay, A.R. Mass spectrometry reveals that the antibiotic simocyclinone D8 binds to DNA gyrase in a “bent-over” conformation: Evidence of positive cooperativity in binding. Biochemistry 2011, 50, 3432–3440. [CrossRef] [PubMed]
10. Hearnshaw, S.J.; Edwards, M.J.; Stevenson, C.E.; Lawson, D.M.; Maxwell, A. A New crystal structure of the bifunctional antibiotic simocyclinone D8 bound to DNA gyrase gives fresh insight into the mechanism of inhibition. J. Mol. Biol. 2014, 426, 2023–2033. [CrossRef] [PubMed]
11. Cheng, G.; Hao, H.; Dai, M.; Liu, Z.; Yuan, Z. Antibacterial action of quinolones: From target to network. Eur. J. Med. Chem. 2013, 66, 555–562. [CrossRef] [PubMed]
12. Aldred, K.J.; Blower, T.R.; Kerns, R.J.; Berger, J.M.; Osheroff, N. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase. Proc. Natl. Acad. Sci. USA 2016, 113, E839–E846. [CrossRef] [PubMed]
13. Shadrick, W.R.; Ndjomou, J.; Kolli, R.; Mukherjee, S.; Hanson, A.M.; Frick, D.N. Discovering new medicines targeting helicases: Challenges and recent progress. J. Biomol. Screen. 2013, 18, 761–781. [CrossRef] [PubMed]
14. Li, B.; Pai, R.; Di, M.; Aiello, D.; Barnes, M.H.; Butler, M.M.; Tashjian, T.F.; Peet, N.P.; Bowlin, T.L.; Moir, D.T. Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: Chemical optimization, biological evaluation, and antibacterial activities. J. Med. Chem. 2012, 55, 10896–10908. [CrossRef] [PubMed]
15. Aiello, D.; Barnes, M.H.; Biswas, E.E.; Biswas, S.B.; Gu, S.; Williams, J.D.; Bowlin, T.L.; Moir, D.T. Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases. Bioorg. Med. Chem. 2009, 17, 4466–4476. [CrossRef] [PubMed]
16. Chopra, S.; Matsuyama, K.; Tran, T.; Malerich, J.P.; Wan, B.; Franzblau, S.G.; Lun, S.; Guo, H.; Maiga, M.C.; Bishai, W.R.; et al. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 2011, 67, 415–421. [CrossRef] [PubMed]
17. Jeankumar, V.U.; Reshma, R.S.; Janupally, R.; Saxena, S.; Sridevi, J.P.; Medapi, B.; Kulkarni, P.; Yogeeswari, P.; Sriram, D. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: Lead optimization and structure activity profiling. Org. Biomol. Chem. 2015, 13, 2423–2431. [CrossRef] [PubMed]
18. Jeyachandran, M.; Ramesh, P.; Sriram, D.; Senthilkumar, P.; Yogeeswari, P. Synthesis and in vitro antitubercular activity of 4-aryl/alkylsulfonylmethylcoumarins as inhibitors of Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 2012, 22, 4807–4809. [CrossRef] [PubMed]
19. Anand, A.; Kulkarni, M.V.; Joshi, S.D.; Dixit, S.R. One pot Click chemistry: A three component reaction for the synthesis of 2-mercaptobenzimidazole linked coumarinyl triazoles as anti-tubercular agents. Bioorg. Med. Chem. Lett. 2016, 26, 4709–4713. [CrossRef] [PubMed]
20. Reddy, D.S.; Hosamani, K.M.; Devarajegowda, H.C. Design, synthesis of benzocoumarin-pyrimidine hybrids as novel class of antitubercular agents, their DNA cleavage and X-ray studies. Eur. J. Med. Chem. 2015, 101, 705–715. [CrossRef] [PubMed]
21. Zheng, P.; Somersan-Karakaya, S.; Lu, S.; Roberts, J.; Pingle, M.; Warrier, T.; Little, D.; Guo, X.; Brickner, S.J.; Nathan, C.F.; et al. Synthetic calanolides with bactericidal activity against replicating and nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 2014, 57, 3755–3772. [CrossRef] [PubMed]
22. Basanagouda, M.; Jambagi, V.B.; Barigidad, N.N.; Laxmeshwar, S.S.; Devaru, V.; Narayanachar. Synthesis, structure-activity relationship of iodinated-4-aryloxymethyl-coumarins as potential anti-cancer and anti-mycobacterial agents. Eur. J. Med. Chem. 2014, 74, 225–233. [CrossRef] [PubMed]
23. Skalicka-Wo´ zniak, K.; Orhan, I.E.; Cordell, G.A.; Nabavi, S.M.; Budzy´ nska, B. Implication of coumarins towards central nervous system disorders. Pharmacol. Res. 2016, 103, 188–203. [CrossRef] [PubMed]
24. Carradori, S.; D’Ascenzio, P.; Chimenti, D.; Secci, A.; Bolasco, A. Selective MAO-B inhibitors. Mol. Div. 2016, 254, 219–243.
25. De Souza, L.G.; Rennó, M.N.; Figueroa-Villar, J. Coumarins as cholinesterase inhibitors: A review. Chem. Biol. Interact. 2016, 254, 11–23. [CrossRef] [PubMed]
26. Joubert, J.; Foka, G.B.; Repsold, B.P.; Oliver, D.W.; Kapp, E.; Malan, S.F. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2017, 125, 853–864. [CrossRef] [PubMed]
27. Patil, P.O.; Bari, S.B.; Firke, S.D.; Deshmukh, P.K.; Donda, S.T.; Patil, D.A. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer’s disease. Bioorg. Med. Chem. 2013, 21, 2434–2450. [CrossRef] [PubMed]
28. Birks, J.; Harvey, R.J. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev. 2006, 1, CD001190.
29. Kuhn, M.L.; Alexander, E.; Minasov, G.; Page, H.J.; Warwrzak, Z.; Shuvalova, L.; Flores, K.J.; Wilson, D.J.; Shi, C.; Aldrich, C.C.; et al. Structure of the essential Mtb FadD32 Enzyme: A promising drug target for treating tuberculosis. ACS Infect. Dis. 2016, 2, 579–591. [CrossRef] [PubMed]
30. Maruri, F.; Sterling, T.R.; Kaiga, A.W.; Blackman, A.; van der Heijden, Y.F.; Mayer, C.; Cambau, E.; Aubry, A. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J. Antimicrob. Chemother. 2012, 67, 819–831. [CrossRef] [PubMed]
31. Carroll, P.; Schreuder, L.J.; Muwanguzi-Karugaba, J.; Wiles, S.; Robertson, B.D.; Ripoll, J.; Ward, T.H.; Bancroft, G.J.; Schaible, U.E.; Parish, T. Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters. PLoS ONE 2010, 5, e9823. [CrossRef] [PubMed]
32. Abrahams, G.L.; Kumar, A.; Savvi, S.; Hung, A.W.; Wen, S.; Abell, C.; Barry, C.E.; Sherman, D.R.; Boshoff, H.I.; Mizrahi, V. Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening. Chem. Biol. 2012, 19, 844–854. [CrossRef] [PubMed]
33. Lounis, N.; Vranckx, L.; Gevers, T.; Kaniga, K.; Andries, K. In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis. Med. Mal. Infect. 2016, 46, 220–225. [CrossRef] [PubMed]
34. Dockal, M.; Carter, D.C.; Ruker, F. Conformational transitions of the three recombinant domains of human serum albumin depending on pH. J. Biol. Chem. 2000, 275, 3042–3050. [CrossRef] [PubMed]
35. Ran, D.; Wu, X.; Zheng, J.; Yang, J.; Zhou, H.; Zhang, M.; Tang, Y. Study on the interaction between Florasulam and bovine serum albumin. J. Fluoresc. 2007, 17, 721–726. [CrossRef] [PubMed]
36. Tian, J.; Liu, J.; Zhang, J.; Hu, Z.; Chen, X. Fluorescence studies on the interactions of barbaloin with bovine serum albumin. Chem. Pharm. Bull. 2003, 51, 579–582. [CrossRef] [PubMed]
37. Seetharamappa, J.; Kamat, B.P. Spectroscopic studies on the mode of interaction of an anticancer drug with bovine serum albumin. Chem. Pharm. Bull. (Tokyo) 2004, 52, 1053–1057. [CrossRef] [PubMed]
38. Sulkowska, A.; Rownicka, J.; Bojko, B.; Sulkowski, W. Interaction of anticancer drugs with human and bovine serum albumin. J. Mol. Struct. 2003, 651, 133–140. [CrossRef]
39. Kun, R.; Kis, L.; Dekany, I. Hydrophobization of bovine serum albumin with cationic surfactants with different hydrophobic chain length. Colloids Surf. B Biointerfaces 2010, 79, 61–68. [CrossRef] [PubMed]
40. Liu, B.; Guo, Y.; Wang, J.; Xu, R.; Wang, X.; Wang, D.; Zhang, L.; Xu, Y. Spectroscopic studies on the interaction and sonodynamic damage of neutral red (NR) to bovine serum albumin (BSA). J. Lumin. 2010, 130, 1036–1043. [CrossRef]
41. Xiang, G.; Tong, C.; Lin, H. Nitroaniline isomers interaction with bovine serum albumin and toxicological implications. J. Fluoresc. 2007, 17, 512–521. [CrossRef] [PubMed]
42. Hu, Y.; Liu, Y.; Zhang, L.; Zhao, R.; Qu, S. Studies of interaction between colchicine and bovine serum albumin by fluorescence quenching method. J. Mol. Struct. 2005, 750, 174–178. [CrossRef]
43. G k, E.; zt rk, C.; Akbay, N. Interaction of Thyroxine with 7 Hydroxycoumarin: A fluorescence quenching study. J. Fluoresc. 2008, 18, 781–785. [CrossRef] [PubMed]
44. Xu, H.; Gao, S.; Lv, J.; Liu, Q.; Zuo, Y.; Wang, X. Spectroscopic investigations on the mechanism of interaction of crystal violet with bovine serum albumin. J. Mol. Struct. 2009, 919, 334–338. [CrossRef]
45. Shaikh, S.M.T.; Seetharamappa, J.; Kandagal, P.B.; Manjunatha, D.H.; Ashoka, S. Spectroscopic investigations on the mechanism of interaction of bioactive dye with bovine serum albumin. Dyes Pigment. 2007, 74, 665–671. [CrossRef]
46. Papadopoulou, A.; Green, R.J.; Frazier, R.A. Interaction of flavonoids with bovine serum albumin: A fluorescence quenching study. J. Agric. Food Chem. 2005, 53, 158–163. [CrossRef] [PubMed]
47. Shi, X.; Li, X.; Gui, M.; Zhou, H.; Yang, R.; Zhang, H.; Jin, Y. Studies on interaction between flavonoids and bovine serum albumin by spectral methods. J. Lumin. 2010, 130, 637–644. [CrossRef]
48. Ware, W.R. Oxygen quenching of fluorescence in solution: An experimental study of the diffusion process. J. Phys. Chem. 1962, 66, 455–458. [CrossRef]
49. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63. [CrossRef]
50. Cui, W.; Zhang, Z.; Li, W.; Hu, S.; Mak, S.; Zhang, H.; Han, R.; Yuan, S.; Li, S.; Sa, F.; et al. The anti-cancer agent SU4312 unexpectedly protects against MPP(+)-induced neurotoxicity via selective and direct inhibition of neuronal NOS. Br. J. Pharmacol. 2013, 168, 1201–1214. [CrossRef] [PubMed]
51. Jantas, D.; Greda, A.; Golda, S.; Korostynski, M.; Grygier, B.; Roman, A.; Pilc, A.; Lason, W. Neuroprotective effects of metabotropic glutamate receptor group II and III activators against MPP(+)-induced cell death in human neuroblastoma SH-SY5Y cells: The impact of cell differentiation state. Neuropharmacology 2014, 83, 36–53. [CrossRef] [PubMed]
52. Pyszko, J.; Strosznajder, J.B. Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells. Mol. Neurobiol. 2014, 50, 38–48. [CrossRef] [PubMed]
53. Wang, Y.; Gao, J.; Miao, Y.; Cui, Q.; Zhao, W.; Zhang, J.; Wang, H. Pinocembrin protects SH-SY5Y cells against MPP+-induced neurotoxicity through the mitochondrial apoptotic pathway. J. Mol. Neurosci. 2014, 53, 537–545. [CrossRef] [PubMed]
54. Nakaso, K.; Tajima, N.; Horikoshi, Y.; Nakasone, M.; Hanaki, T.; Kamizaki, K.; Matsura, T. The estrogen receptor beta-PI3K/Akt pathway mediates the cytoprotective effects of tocotrienol in a cellular Parkinson’s disease model. Biochim. Biophys. Acta 2014, 1842, 1303–1312. [CrossRef] [PubMed]
55. Tasaki, Y.; Omura, T.; Yamada, T.; Ohkubo, T.; Suno, M.; Iida, S.; Sakaguchi, T.; Asari, M.; Shimizu, K.; Matsubara, K. Meloxicam protects cell damage from 1-methyl-4-phenyl pyridinium toxicity via the phosphatidylinositol 3-kinase/Akt pathway in human dopaminergic neuroblastoma SH-SY5Y cells. Brain Res. 2010, 1344, 25–33. [CrossRef] [PubMed]
56. Zhu, G.; Wang, X.; Wu, S.; Li, Q. Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+-induced human neuroblastoma SH-SY5Y cell death. Neurochem. Int. 2012, 60, 400–408. [CrossRef] [PubMed]
57. Ioerger, T.R.; Feng, Y.; Ganesula, K.; Chen, X.; Dobos, K.M.; Fortune, S.; Jacobs, W.R., Jr.; Mizrahi, V.; Parish, T.; Rubin, E.; et al. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J. Bacteriol. 2010, 192, 3645–3653. [CrossRef] [PubMed]
58. Goldstone, R.M.; Goonesekera, S.D.; Bloom, B.R.; Sampson, S.L. The transcriptional regulator Rv0485 modulates the expression of a pe and ppe gene pair and is required for Mycobacterium tuberculosis virulence. Infect. Immun. 2009, 77, 4654–4667. [CrossRef] [PubMed]
59. Ollinger, J.; Bailey, M.A.; Moraski, G.C.; Casey, A.; Florio, S.; Alling, T.; Miller, M.J.; Parish, T. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. PLoS ONE 2013, 8, e60531. [CrossRef] [PubMed]